Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 11855.145 | 1.0025 | 1.0100 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 11855.145 | 0.9252 | 0.7158 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 11855.145 | 0.8182 | 0.3464 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 11855.145 | 0.2963 | -0.8184 | 0.5070 | |
| BT-483 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 11855.145 | 0.6513 | -0.1416 | 0.5070 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0000853 | uM | 12305.17 | 0.9309 | 0.9490 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.000427 | uM | 12305.17 | 0.9889 | 0.9919 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.00213 | uM | 12305.17 | 1.0224 | 1.0161 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0107 | uM | 12305.17 | 0.9227 | 0.9428 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.0533 | uM | 12305.17 | 0.9655 | 0.9749 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 0.267 | uM | 12305.17 | 0.7732 | 0.8228 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 1.33 | uM | 12305.17 | 0.5678 | 0.6307 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 6.67 | uM | 12305.17 | 0.0219 | -0.4961 | 2.7728 | |
| BT-549 | TNBC | Basal B | Bosutinib | Src | nRTK | 33.3 | uM | 12305.17 | 0.0160 | -0.5499 | 2.7728 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 10755.145 | 0.9449 | 0.8580 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 10755.145 | 0.9087 | 0.7658 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.0064 | uM | 10755.145 | 0.9187 | 0.7911 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.032 | uM | 10755.145 | 0.9387 | 0.8420 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.16 | uM | 10755.145 | 1.0124 | 1.0324 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.8 | uM | 10755.145 | 0.9333 | 0.8283 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 4 | uM | 10755.145 | 0.9043 | 0.7548 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 20 | uM | 10755.145 | 0.7730 | 0.4308 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 100 | uM | 10755.145 | 0.7463 | 0.3670 | 0.7688 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.000256 | uM | 12070.145 | 0.8006 | 0.6259 | 1.0737 | |
| CAMA-1 | HR+ | Luminal | Bosutinib | Src | nRTK | 0.00128 | uM | 12070.145 | 0.9270 | 0.8636 | 1.0737 |